Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)
Beam Therapeutics announced significant progress in Q2 2026, including dosing the first patient in a pivotal cohort for BEAM-302 in alpha-1 antitrypsin deficiency, completion of dosing in the BEACON trial for sickle cell disease with risto-cel, FDA clearance for BEAM-304 clinical trial in phenylketonuria, and a strong cash position supporting opera…